Genasense Perifosine Flavopiridol Bevacizumab (Avastin) Sorafenib plus 17-AAG Sorafenib plus temsirolimus Imatinib plus Sunitinib 17-AAG (tanespimycin, KOS-953) and Bortezomib

Imatinib (Gleevec) Plus Sunitinib (Sutent)

Both these drugs are already approved for GIST:

• Gleevec (from Novartis) is approved for inoperable or metastatic GIST
• Sutent (from Pfizer)  is approved for GIST in patients who are intolerant of imatinib, or who have grown resistant to imatinib

The planned Phase I combination trial, which is not yet recruiting, is described at clinicaltrials.gov